Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes

Diabetes Care

Volumn 28, Issue 1, 2005, Pages 10-14

  Kudva, Yogish C ^a   Basu, Ananda ^a   Jenkins, Gregory D ^a   Pons, Guillermo M ^b   Quandt, Lori L ^a   Gebel, Julie A ^a   Vogelsang, Debra A ^b   Smith, Steven A ^a   Rizza, Robert A ^a   Isley, William L ^a  

^a MAYO CLINIC   (United States)

^b Immanuel St Joseph's Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN ZINC SUSPENSION;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MONITORING, AMBULATORY;

EID: 19944427445     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.1.10     Document Type: Article

References (11)

1. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
2. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639-643, 2000
3. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-1671, 2000
4. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ: Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 303:1313-1318, 1980
5. Rizza R, O'Brien P, Service F: Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM. Diabetes Care 9:120-123, 1986
6. Freeman SL, O'Brien PC, Rizza RA: Use of human ultralente as the basal insulin component in treatment of patients with IDDM. Diabetes Res Clin Pract 12:187-192, 1991
7. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
8. Service FJ, O'Brien PC, Rizza RA: Measurements of glucose control. Diabetes Care 10:225-237, 1987
9. Cox D, Irvine A, Gonder-Frederick L, Nowacek G, Buterfiled J: Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 10:617-621, 1987
10. Ritzel RA, Veldhuis JD, Butler PC: Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships. J Clin Endocrinol Metab 88:742-747, 2003
11. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996